Jabbour on Tailoring Treatment With TKIs in CML and Ph+ ALL

In Partnership With:

Partner | Cancer Centers | <b>The University of Texas MD Anderson Cancer Center</b>

Dr. Jabbour discusses the optimal use of ponatinib in chronic myeloid leukemia and data from the 2021 ASCO Annual Meeting with the combination of blinatumomab and ponatinib in Ph-positive acute lymphoblastic leukemia.

Welcome to OncLive On Air®! I’m your host today, Jessica Hergert.

OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, sponsored by Takeda, we had the pleasure of speaking with Elias Jabbour, MD, a professor in the Department of Leukemia and Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, to discuss the use of TKIs in the treatment of patients with chronic myeloid leukemia (CML) and Philadelphia (Ph) chromosome–positive acute lymphoblastic leukemia (ALL).

In our exclusive interview, Jabbour discussed the optimal use of ponatinib in CML, recommendations for the treatment of patients with chronic phase–CML who progress after second-generations TKIs, and data from the 2021 ASCO Annual Meeting with the combination of blinatumomab (Blincyto) and ponatinib (Iclusig) in Ph-positive ALL.